Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: phoenix_rising who wrote (1434)	8/13/2015 7:35:50 AM
From: mokelumne river	Read Replies (1) \| Respond to of 2026

PR, not that I am optimistic, but Apricus can offer RTD to Allergan and shave at least a year or two of time to market RTD. Allergan would still have to go through the FDA, but using RTD instead of cold chain Vitaros for the clinical trials. Otherwise, Allergan would have to go through its own room temperature device development and shelf life studies, I would think, since RTD is patented. Less time to marketing in the U$ market with the allowance of advertising could be a big deal with a product "proven effective in men throughout Europe," not to mention Singapore. ; )